Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides each representing strategically important niches with their own competitive dynamics
Rare: mild nausea (brief, self-resolving)
However, some groups of people are more at risk of deficiency than others and may wish to discuss the possibility of B12 shots with their doctor
If you are past that window and still feel worse, that is your signal to get checked rather than to keep going
Here is how BPC-157 may indirectly support muscle growth: So while BPC-157 is not going to pack on slabs of muscle by itself, it can serve as a powerful tool within a well-rounded approach to training, nutrition, and recovery
the "PDA counterion argument" for regulatory compliance has not been validated by FDA guidance as of April 2026